Humacyte, Inc. (NASDAQ:HUMA) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Moderate Buy consensus from eight analysts (seven buys, one sell) with an average 12‑month price target of $8.14; individual targets range roughly $3 to $10 and Benchmark recently trimmed its target to $10.
• Shares trade near $1.01 (50‑day $1.08, 200‑day $1.42) with a 52‑week range of $0.88–$4.14 and a market cap of about $189M; the company has a negative P/E, high debt‑to‑equity (2.97) and institutional ownership of ~44.7% after recent stake increases by Vanguard, Geode, UBS and others.
• Humacyte is a clinical‑stage biotech developing off‑the‑shelf regenerative human acellular vessels (HAVs) for vascular access, with trials showing durability and reduced infection rates in hemodialysis patients.

Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the eight analysts that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $8.1429.

HUMA has been the topic of several recent research reports. BTIG Research reiterated a "buy" rating and issued a $6.00 price target on shares of Humacyte in a report on Monday, February 9th. HC Wainwright reissued a "buy" rating and issued a $3.00 price target on shares of Humacyte in a report on Monday, December 1st. Weiss Ratings reiterated a "sell (d-)" rating on shares of Humacyte in a report on Monday, December 29th. UBS Group restated a "buy" rating on shares of Humacyte in a report on Monday, December 1st. Finally, Benchmark dropped their price target on shares of Humacyte from $11.00 to $10.00 and set a "buy" rating on the stock in a research report on Wednesday, January 21st.

Humacyte Stock Performance

Shares of NASDAQ HUMA opened at $1.01 on Tuesday. The business's 50-day simple moving average is $1.08 and its 200-day simple moving average is $1.42. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.90 and a current ratio of 1.62. Humacyte has a 52 week low of $0.88 and a 52 week high of $4.14. The firm has a market cap of $189.14 million, a price-to-earnings ratio of -4.39 and a beta of 1.93.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. raised its stake in Humacyte by 7.4% in the third quarter. Vanguard Group Inc. now owns 7,520,055 shares of the company's stock valued at $13,085,000 after purchasing an additional 520,431 shares in the last quarter. Geode Capital Management LLC increased its holdings in Humacyte by 20.2% in the 4th quarter. Geode Capital Management LLC now owns 3,720,436 shares of the company's stock worth $3,574,000 after purchasing an additional 624,220 shares in the last quarter. CenterBook Partners LP increased its holdings in Humacyte by 141.1% in the 2nd quarter. CenterBook Partners LP now owns 3,430,255 shares of the company's stock worth $7,169,000 after purchasing an additional 2,007,743 shares in the last quarter. UBS Group AG increased its stake in shares of Humacyte by 48.8% in the fourth quarter. UBS Group AG now owns 2,978,610 shares of the company's stock valued at $2,862,000 after buying an additional 976,275 shares during the period. Finally, State Street Corp increased its stake in shares of Humacyte by 17.8% in the fourth quarter. State Street Corp now owns 2,837,276 shares of the company's stock valued at $2,725,000 after buying an additional 429,233 shares during the period. 44.71% of the stock is owned by institutional investors.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company's proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient's own tissue. Humacyte's primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company's lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.